AMRI Names Key Leader to Oversee Global Sales Force.

ALBANY, N.Y. -- AMRI (NASDAQ: AMRI) has named Steve Jennings as senior vice president of sales, marketing and business development.

In his new position, Jennings will assume responsibility for all of AMRI's global sales efforts, including sales teams in the U.S., Asia and Europe. He brings over 30 years of leadership and global sales experience, with a strong background in business development and licensing in both the pharmaceutical and medical device sectors. The majority of his career was spent in domestic and international sales management roles at Solvay Pharmaceuticals. During his ten-year tenure there, he rose from regional sales director to vice president of global marketing for the Gastroenterology and Women's Health business units, two of Solvay's largest pharmaceutical business lines. Among his accomplishments at Solvay are leading a 450-person sales force and managing the launch of several products, including one with annual revenue of $200 million.

Prior to Solvay, Jennings held sales leadership roles with both Ciba Geigy (currently Novartis) and Reed and Carnick Pharmaceuticals. Most recently, he was vice president of sales at Cyberonics, Inc., a medical device company specializing in neurological and psychiatric illness. He is a graduate of Middle Tennessee State University and earned an MBA from Keller Graduate School of Management.

"We are pleased to announce the addition of Steve Jennings to AMRI's senior leadership team," said AMRI Chairman, President and CEO Thomas E. D'Ambra. "Steve has an exceptional track record in sales and marketing in the pharmaceutical and medical device industry. We expect him to play a key leadership role in the continued growth of our sales force to support our expanding operations and technologies around the globe. His prior experience in building, training and directing differentiated sales teams will be a key skill as we continue to rapidly expand AMRI's sales presence around the world. His depth of knowledge in the due diligence process of potential product and company acquisitions will bring additional expertise to AMRI's leadership team in its strategic planning process."

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. A separate, standalone R&D division of the company is also developing technology that it intends to partner and outlicense; something viewed as a higher value added service to the many companies AMRI is working with. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on March 15, 2007 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.